Ian Marks’ Post

In advanced cancer care, the complexity of polypharmacy often leads to serious side effects, adverse drug events, and medication inefficacy. A recent study shows that targeted palliative care, focusing on the most impactful symptoms, can reduce the need for extensive medications and improve patient quality of life. With advanced technology enabling earlier cancer detection, we can further minimize the challenges of polypharmacy and enhance patient outcomes. https://bit.ly/3SCRYy3 #CancerCare #Polypharmacy #HealthcareInnovation #PalliativeCare

📰 BREAKING NEWS: Promising new medication offers exciting advancements in slowing early-stage lung cancer development. Key Highlights: 1️⃣ According to company research, AstraZeneca's Tagrisso demonstrates a significant improvement in progression-free survival (PFS) as a maintenance treatment following chemoradiotherapy. 2️⃣ The study hints at a positive trend in overall survival (OS), with further data collection underway. 3️⃣ Should Tagrisso continue to prove effective, countless lives could be saved through critical early intervention. 💬 What are your thoughts on this new development in lung cancer treatment? Share below! 👉 And follow Body Vision Medical for the latest in medical innovation. #LungCancer #CancerTreatment #MedicalInnovation #Healthcare

Oral cancer screenings are crucial for early detection and treatment, but many practices overlook this vital step. Here’s why you should prioritize screenings and the risks of not completing them: Why Oral Cancer Screening Matters: 🔍 Early Detection Saves Lives: Catching oral cancer in its early stages significantly increases the chances of successful treatment and recovery. 💡 Prevent Advanced Disease: Early screening helps prevent cancer from advancing to more severe stages, reducing the need for complex and costly treatments. By prioritizing oral cancer screenings, you enhance patient care, uphold ethical standards, and protect your practice from legal and financial risks. Read more about Vigilant Biosciences' real-time oral cancer detection: https://bit.ly/4chBH9D Ready to elevate your practice and ensure top-notch compliance? The Dental Compliance Institute offers the expertise and resources you need to stay ahead. https://bit.ly/3IL4mat #OralCancerScreening #DentalCare #PatientSafety #DentalInnovation #FDAApproval #PreventiveCare #DentalComplianceInstitute

As we celebrate #NuclearMedicineWeek, Let us shine a spotlight on the recently released 2024 CANM PSMA Guidelines! #Prostatecancer remains a major health challenge, but advancements in #PSMA #PET/CT imaging have transformed the way we diagnose and treat it. These guidelines offer critical insights into the use of PSMA-targeted radiopharmaceuticals like 68Ga-PSMA-11, providing clearer pathways for managing intermediate to high-risk prostate #cancer cases and identifying metastatic disease with greater accuracy. Let’s take a moment to acknowledge the tireless efforts of #nuclearmedicine professionals who continue to innovate and improve patient care. Their work is shaping the future of #oncology diagnostics and treatment. Enjoy the Read #PSMAGuidelines #NuclearMedicine #ProstateCancer #MedicalImaging #HealthcareInnovation

Explore incorporating immunotherapy as part of end-of-life care plans for metastatic cancer patients to potentially extend overall survival. Consult with healthcare professionals to understand the benefits and risks associated with this treatment approach fully. Consider personalized and holistic approaches that take into account individual patient needs and preferences for a comprehensive end-of-life care strategy. #immunotherapy #metastaticcancer #endoflifecare #overallSurvival #holisticapproach BioMedHack.com is your leading source for the latest news, breakthroughs, and insights in medicine, biohacking, and alternative medicine. Our mission is to help you live healthier and longer by bringing you cutting-edge information and expert advice. Follow us on Facebook, Instagram, and X. Read more about this post here: https://lnkd.in/ejdqktED

A major factor contributing to the high lung cancer mortality rate is delayed diagnosis of lung cancer. Many patients are identified at a late stage where metastasis of cancer might have already happened, which limits their treatment options and chances for recovery. AI can help mitigate this challenge by identifying lung nodules (precursors to lung cancer) incidentally on radiological images. This early stage detection can facilitate timely diagnosis and stage shifting of cancer cases. Additionally, AI can do this at scale at a minimal cost ensuring that these benefits can be extended to a larger patient population effectively across the globe.

Lung cancer is one of the deadliest diseases in India, often diagnosed at a late stage when the chances of survival drop drastically. For early-stage lung cancer (stage 1), the five-year survival rate is around 80-90%. However, this plummets to just 10% by stage 4. A significant reason for this high mortality rate is the delayed diagnosis. Many patients only discover they have lung cancer when it has already spread, limiting their treatment options and reducing their chances of recovery. Artificial Intelligence (AI) offers a promising solution to this challenge which can detect lung nodules, which are early indicators of lung cancer, incidentally on radiological images. Early detection can lead to timely diagnosis and potentially shift cancer cases to earlier stages, improving outcomes. Moreover, AI can do this at scale and at a minimal cost, making these benefits accessible to a larger patient population globally. At #qure.ai we are dedicated to transforming healthcare with AI. Our efforts have reached over 2,700 healthcare facilities in more than 90 countries. Specifically, for lung cancer, we have screened over 2.7 million patients in over 30 countries and approximately 400 health centers, making a significant impact worldwide. Our product, QXR, is an AI-powered radiodiagnosis software that uses X-ray imaging for the early detection of diseases like lung cancer, tuberculosis, and stroke. This software is being utilized in over 90 countries to detect conditions such as tuberculosis, lung nodules, and lung cancer, reducing turnaround time by 40% with normal-abnormal triage. We are extremely proud to be making a difference in the fight against lung cancer and other critical diseases.

Have you seen this recent news from ISCT? ISCT is kicking off the year with an important publication of an expert consortium commentary in Nature Medicine addressing a recent statement from the FDA that it is investigating serious risk of T-cell malignancy. Why is this important? CAR T-cell therapy is considered one of the most important breakthroughs in medicine, where a patient's own immune cells are used to treat cancer. So, this news poses the question - What does this investigation mean for patients and the future of CAR T treatments? In this publication, Dr. Bruce Levine sets crucial context for this report – supporting the need for thorough investigation by the FDA while also emphasizing that the rate of malignancies reported for patients following CAR-T cell immunotherapies is substantially lower than other treatment modalities. Therefore these life-saving treatments should be continued to be offered to patients when deemed the best possible option. Learn More: https://lnkd.in/gqVYFbx2 #cellandgenetherapy

Carl June, the father of CAR-T therapy, shares his vision for the future of this transformative treatment. June highlights the significant strides made in CAR T-cell therapy, particularly its application in treating glioblastoma. Once considered nearly untreatable, this devastating disease now shows promise with innovative CAR T-cell infusions. and predicts that within five years, we could see FDA-approved CAR-T therapies for glioblastoma. Thanks to June's groundbreaking research, there are now six approved CAR-T therapies on the market, and over 34,000 blood cancer patients have been treated. As we witness the evolution of CAR T-cell therapy, it's clear that we're just scratching the surface of its potential—not only in cancer treatment but also in addressing autoimmune diseases and even exploring regenerative medicine #CART #Allogeneic #Autologous #Glioblastoma #CancerTreatment #Autoimmunediseases #lupus, #myositis #multiplesclerosis #scleroderma #Glioblastoma #ElixirAssociates

We’re on a quest to fight #LungCancer. Working with global #healthcare institutions, clinical luminaries, innovators and academics to power the development and evidence generation of #AI-powered solutions. To save lives. Together. On this World Lung Cancer Day #WLCD2024, we salute the #collaborative progress being made to #detect #cancer early and express our commitment to ‘casting the net’ wider in lung health surveillance. We will continue to keep the patient at the heart of all our #medicalimaging #AI solutions - to identify lung nodules early; to measure / track volumetric growth as part of progression monitoring; to help manage cases; and to monitor drug efficacy or disease progression in clinical trials and cancer care.     #AIForGood #AIForCancer #EarlyDectection #Oncology #Pulmonology #PharmaAI #MedicalDevices #WorldLungCancerDay #CloseTheCareGap